Release
Savara Reports Second Quarter Financial Results and Provides Business Update
-
Fully Enrolled Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Report Top Line Data by End of 2Q 2024
— 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease
-
~$105M in Cash and Cash Equivalents at the End of 2Q 2023
-
Further Strengthened Balance Sheet in July with an
~$80M Equity Financing, Resulting in~$180M in Pro Forma Cash After Giving Effect to the Offering
-
Anne Erickson , SVP, Global Business Operations, Promoted to Chief Business Officer, Effective Immediately
“The Company continues to make strong progress with the molgramostim development program,” said
Second Quarter Financial Results (Unaudited)
Savara's net loss for the second quarter of 2023 was
Research and development expenses increased by
General and administrative expenses increased by
As of
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (
Forward-Looking Statements
Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements related to the timing of reporting of top line data. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks and uncertainties relating to the impact of widespread health concerns impacting healthcare providers or patients, disruptions or inefficiencies in the supply chain and geopolitical conditions on our business and operations, the outcome of our ongoing and planned clinical trials for our product candidate, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as molgramostim that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the
Financial Information to Follow
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (in thousands, except for share and per share amounts) | ||||||||||||||||
| Unaudited | ||||||||||||||||
|
Three months ended |
|
Six months ended |
||||||||||||||
|
|
|
|
||||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
||
| Operating expenses: | ||||||||||||||||
| Research and development |
$ |
8,911 |
|
$ |
6,418 |
|
$ |
17,649 |
|
$ |
12,102 |
|
||||
| General and administrative |
|
3,302 |
|
|
2,957 |
|
|
6,668 |
|
|
5,311 |
|
||||
| Depreciation and amortization |
|
8 |
|
|
8 |
|
|
16 |
|
|
16 |
|
||||
| Total operating expenses |
|
12,221 |
|
|
9,383 |
|
|
24,333 |
|
|
17,429 |
|
||||
| Loss from operations |
|
(12,221 |
) |
|
(9,383 |
) |
|
(24,333 |
) |
|
(17,429 |
) |
||||
| Other income (expense), net: |
|
778 |
|
|
219 |
|
|
2,333 |
|
|
(35 |
) |
||||
| Net loss attributable to common stockholders |
$ |
(11,443 |
) |
$ |
(9,164 |
) |
$ |
(22,000 |
) |
$ |
(17,464 |
) |
||||
| Net loss per share - basic and diluted |
$ |
(0.07 |
) |
$ |
(0.06 |
) |
$ |
(0.14 |
) |
$ |
(0.11 |
) |
||||
| Weighted average shares - basic and diluted |
|
152,796,617 |
|
|
152,771,103 |
|
|
152,778,031 |
|
|
152,770,434 |
|
||||
| Other comprehensive loss |
|
(158 |
) |
|
(725 |
) |
|
(14 |
) |
|
(1,021 |
) |
||||
| Total comprehensive loss |
$ |
(11,601 |
) |
$ |
(9,889 |
) |
$ |
(22,014 |
) |
$ |
(18,485 |
) |
||||
| Condensed Consolidated Balance Sheet Data | ||||||
| (in thousands) | ||||||
| (Unaudited) | ||||||
|
|
|
|
||||
|
|
2023 |
|
|
2022 |
||
| Cash, cash equivalents, and short-term investments |
$ |
105,179 |
$ |
125,876 |
||
| Working capital |
|
102,015 |
|
123,087 |
||
| Total assets |
|
119,833 |
|
139,777 |
||
| Total liabilities |
|
32,118 |
|
31,999 |
||
| Stockholders’ equity: |
|
87,715 |
|
107,778 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20230810730094/en/
(512) 851-1366
Source:
Email Alerts
Enter your e-mail address to receive alerts whenever certain new company information is posted to this site